Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Essential oils (EOs) of Thymus capitatus (Th) carvacrol chemotype and Origanum vulgare (Or) thymol and carvacrol chemotype were encapsulated in biocompatible poly(ε-caprolactone) nanocapsules (NCs). These nanosystems exhibited antibacterial, antifungal, and antibiofilm activities against Staphylococcus aureus, Escherichia coli, and Candida albicans. Th-NCs and Or-NCs were more effective against all tested strains than pure EOs and at the same time were not cytotoxic on HaCaT (T0020001) human keratinocyte cell line. The genotoxic effects of EO-NCs and EOs on HaCaT were evaluated using an alkaline comet assay for the first time, revealing that Th-NCs and Or-NCs did not induce DNA damage compared with untreated control HaCaT cells in vitro after 24 h. The cells morphological changes were assessed by label-free live cell Raman imaging. This study demonstrate the ability of poly(ε-caprolactone) nanocapsules loaded with thyme and oregano EOs to reduce microbial and biofilm growth and could be an ecological alternative in the development of new antimicrobial strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijpharm.2021.120846 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Overview on Lipid Nanocapsules: Exploring the Role in Precision Cancer Treatment and Lymphatic Drug Distribution.
Adv Pharm Bull
July 2025
Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, India.
Lipid nanocapsules (LNCs) are an emerging nanocarrier platform for cancer therapy as they can co-deliver multiple drugs, promote synergistic action, and provide targeted drug delivery. The phase inversion temperature (PIT) process is most used for LNC formulation, which has the advantage of process simplicity, thermodynamic stability, and the employment of non-toxic solvents without requiring high energy input. Surface functionalization with targeting ligands like folic acid and peptides increases tumor specificity and reduces off-target toxicity.
View Article and Find Full Text PDFLeveraging Nanotechnology for Safer Herbicide Use: Insights from Maize Tolerance to Nanoencapsulated Atrazine.
ACS Omega
September 2025
Department of Animal and Plant Biology, State University of Londrina (UEL), Londrina, Paraná 86057-970, Brazil.
Previous work has shown that nanoencapsulation of atrazine enhances the herbicidal action of this active ingredient. This increased activity is expected to control weeds and not compromise the tolerance of maize plants to the herbicide. This study aimed to evaluate the tolerance of maize plants to atrazine in postemergence application with different nanoformulations.
View Article and Find Full Text PDFMetabolic Inhibitor Loaded Metal-Phenolic Nanocapsules Enable Synergistic Cancer Therapy through Cuproptosis and Immunometabolic Reprogramming.
ACS Appl Mater Interfaces
September 2025
Medical Science and Technology Innovation Center, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China.
Abnormal glycolysis and glutamine metabolism not only sustain tumor growth but also reprogram the tumor microenvironment (TME). However, due to compensatory mechanisms and low tumor immunogenicity, targeting a single metabolic pathway is often insufficient for effective cancer therapy. We here developed dual-starvation therapeutic metal-phenolic nanocapsules (CG@Cap) by encapsulating a glutamine metabolism inhibitor with a zeolitic imidazolate framework-8 and adsorbing glucose oxidase on the surface, followed by coordination-driven assembly with tannic acid and copper ions.
View Article and Find Full Text PDFAdvances in the application of lipid nanocapsules and nanostructured carriers in the treatment of lung cancer.
Nanomedicine (Lond)
September 2025
Département des Technologies pour l'Innovation en Santé, Université Grenoble-Alpes, CEA-LETI, Grenoble, France.
Lung cancer remains the leading cause of cancer-related deaths worldwide, with limited curative options, particularly in advanced stages. Lipid-based nanocarriers, including liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and lipid nanocapsules (LNCs), have emerged as promising drug delivery platforms owing to their biocompatibility, versatility, and potential for pulmonary administration. This review highlights recent advances in lipid nanocarriers for lung cancer therapy, with a particular focus on NLCs and LNCs.
View Article and Find Full Text PDFHydrophobic drug delivery via oral or pulmonary routes presents significant challenges for clinical translation, particularly for poorly soluble antiviral drugs. Physiological barriers-such as enzymatic degradation, harsh pH, and rapid transit in the gastrointestinal tract, or mucociliary clearance and alveolar macrophage uptake in the lungs-can severely limit therapeutic efficacy. To address these challenges, we developed a novel lipid nanocapsule (LNC) and chitosan/iota-carrageenan hydrogel composite tailored for sustained delivery of hydrophobic antiviral agents.
View Article and Find Full Text PDF